An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Original Article

K.C. Herold, B.N. Bundy, S.A. Long, J.A. Bluestone, L.A. DiMeglio, M.J. Dufort, S.E. Gitelman, P.A. Gottlieb, J.P. Krischer, P.S. Linsley, J.B. Marks, W. Moore, A. Moran, H. Rodriguez, W.E. Russell, D. Schatz, J.S. Skyler, E. Tsalikian, D.K. Wherrett, A.-G. Ziegler, and C.J. Greenbaum

N Engl J Med 2019;381:603-613

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
08/14/2019
Course expires: 
08/15/2021

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Course closed

This course closed on Sunday, August 15, 2021 - 11:59pm.